3D IMAGING DRUG DESIGN & DEVELOPMENT LLC

3D IMAGING DRUG DESIGN & DEVELOPMENT LLC specializes in the design, synthesis, and delivery of radiotracers for biomedical research and diagnostic applications, leveraging advanced 3D imaging techniques to support drug development workflows. The company’s core expertise lies in radiochemistry, molecular imaging, and the engineering of targeted radiolabeled compounds for use in preclinical and clinical settings. Their work integrates physical chemistry, nuclear medicine, and computational modeling to optimize tracer kinetics, biodistribution, and signal-to-noise ratios—critical factors in PET and SPECT imaging. Key differentiators include precision synthesis methodologies and end-to-end delivery systems that bridge laboratory innovation with operational feasibility in regulated environments. The contractor has delivered services to the Department of Health and Human Services, specifically supporting initiatives under 18F focused on digital health infrastructure. Their engagement centers on developing and deploying radiotracer technologies that enhance diagnostic accuracy and accelerate therapeutic evaluation, aligning with HHS priorities in precision medicine and imaging innovation. The primary NAICS code, 541715, reflects a focus on research and development in the life sciences, excluding nanotechnology and biotechnology. This positions the firm squarely within the radiopharmaceutical and molecular imaging sector, serving the growing demand for non-invasive diagnostic tools in oncology, neurology, and cardiology. Their market niche is defined by technical rigor in tracer development and a systems-level approach to imaging agent delivery. As a small business structured under the 2K designation, the company operates from Little Rock, Arkansas, with no federal certifications on record. While limited in public certification status, its specialized technical output demonstrates a focused capability in a high-barrier, high-impact segment of the federal life sciences market.